• Contact
  • Careers
    •
  • About us
  • Who we are
  • Mission, vision and values
  • Management board
  • Supervisory board
  • Scientific advisory board
  • Partnering
    •
  • Our technology
  • What we are targeting
  • Mechanism of Action
  • M6229
    •
  • Pipeline
  • Pipeline
  • Clinical trials
  • IP position
    •
  • Sepsis & septic shock
  • What is sepsis?
  • Current treatment
  • Health impact
  • Economic impact
    •
  • News
  • About us
  • Who we are
  • Mission, vision and values
  • Management board
  • Supervisory board
  • Scientific advisory board
  • Partnering
    •
  • Our technology
  • What we are targeting
  • Mechanism of Action
  • M6229
    •
  • Pipeline
  • Pipeline
  • Clinical trials
  • IP position
    •
  • Sepsis & septic shock
  • What is sepsis?
  • Current treatment
  • Health impact
  • Economic impact
    •
  • News
  • Contact
  • Careers
    •
    Who we are

    Who we are

    Matisse Pharmaceuticals BV is a biopharmaceutical clinical stage company dedicated to develop a product portfolio of safe and innovative therapies for disease indications characterized by elevated levels of cell free cytotoxic histones, such as in sepsis and septic shock.

    Strategy

    The strategy of Matisse Pharmaceuticals is to maximize the value of its novel treatments by advancing the preclinical and clinical development in the fastest, most efficient and cost-effective way possible.

    History

    Matisse Pharmaceuticals BV was founded in 2014 with the main objective to develop the therapeutic product M6229 for the treatment of sepsis. Matisse Pharmaceuticals is based at the Brightlands Chemelot Campus in Geleen, The Netherlands.

    Mission, vision and values